{"entity":{"id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","aka":[],"tldr":"A phase 1/2 trial of Radiopharmaceuticals in prostate cancer, run by C Ray Therapeutics, now recruiting.","summary":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC is a phase 1/2 interventional study registered as NCT07567521 by C Ray Therapeutics, with 90 participants planned, started 2026-05-22 and due to reach its primary completion in 2027-12-30. Interventions recorded: Radiopharmaceuticals.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07567521","url":"https://clinicaltrials.gov/study/NCT07567521"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07567521","phase":"1/2","setting":"A Prospective, Open-label, Randomized, Phase 1/2 Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)","sponsor":"C Ray Therapeutics","started":"2026-05-22","startedType":"actual","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07567521/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}]}}